ClinicalTrials.gg
RecruitingNCT07444853TIPITCHUpdated May 6, 2026

Improving the Prognosis for Cerebral Hemorrhage A Study of Clinical, Biological, and Imaging Markers

An observational study in Intracerebral Hemorrhage (ICH), sponsored by University Hospital, Tours. Recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University Hospital, Tours · Observational

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Cerebral Hemorrhage with a site in France — 11 open to participants now, 11 under way, 2 of them phase 3. Cerebral Hemorrhage · France.

Planned enrollment
Largest of 11
10,000 · median 455
Started
2026
with 4 others
Observational
11 of 24
7 open now
Primary completion
2036-04
later than 10 of 10 live
Registered
23rd of 24
by date
Lead sponsor
2 of 24
University Hospital, Tours

Among the 24 studies in Cerebral Hemorrhage with a site in France, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 5 that started in 2026, is one of 11 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 23rd registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

11 of the 24 studies in Cerebral Hemorrhage with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Cerebral Hemorrhage with a site in France, or all of them as a file.
02

Study summary

This study will establish a prospective, multicenter national cohort of patients with spontaneous intracerebral hemorrhage (ICH). A standardized multimodal database integrating clinical, biological, and imaging data will be collected.

The study aims to better characterize ICH patient phenotypes, identify diagnostic and prognostic biomarkers, and describe adherence to evidence-based acute management strategies, including the proportion of patients managed according to the care bundle validated in the INTERACT 3 study.

The cohort is also intended to provide a structured platform for translational research and the preparation of future stratified interventional clinical trials in spontaneous ICH.

Read the detailed description

This prospective, multicenter national cohort study in ICH is designed to support comprehensive clinical, biological, imaging, and process-of-care characterization of patients.

A centralized and harmonized biobank will be established to enable the collection and analysis of biological samples, with a focus on biomarkers related to inflammation, hematoma resorption, and genetic susceptibility.

A standardized and interoperable imaging database will be implemented to allow quantitative analysis of hemorrhagic lesions, including hematoma volume, hematoma expansion, perihematomal edema, and their temporal evolution over time.

The study will also document acute ICH management practices, including the proportion of patients managed according to the evidence-based care bundle validated in the INTERACT 3 study. Components of this bundle include early intensive blood pressure control, reversal of anticoagulation when applicable, maintenance of blood glucose within recommended targets, body temperature control, and systematic neurosurgical consultation. Adherence to these components will be recorded as part of routine care.

The cohort will rely on a network of participating clinical and research centers trained and equipped to apply standardized procedures for patient inclusion, data collection, imaging acquisition, and biospecimen handling, with the objective of promoting harmonized clinical practice and high-quality data generation.

Finally, the cohort is intended to serve as a structured platform to support the design and implementation of future stratified interventional clinical trials in spontaneous ICH, based on phenotypic, biomarker, imaging, and care-process data generated within the cohort.

03

Conditions studied

  • Intracerebral Hemorrhage (ICH)

Keywords

  • diagnostic and prognostic biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with spontaneous intracerebral hemorrhage included in 4 centers.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years;
  • Emergency admission to a participating center, with spontaneous intracerebral hemorrhage confirmed by the first brain imaging (CT or MRI) performed at the time of initial treatment;
  • Obtaining non-opposition

Exclusion criteria

Exclusion Criteria:

  • First brain imaging performed outside a center participating in the study (e.g., peripheral center not recruiting);
  • Intracerebral hemorrhage secondary to another identified condition, including:

    • vascular malformation (aneurysm, arteriovenous malformation, cavernoma, etc.);
    • intracranial tumor;
    • hemorrhagic transformation of a cerebral infarction;
    • recent head trauma.
  • Patient under legal protection;
  • Patient under guardianship or conservatorship.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
10,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Number of patients enrolled in the TIPITCH registry with a data completion rate ' ≥ 80% across the three main components of the registry, defined as:

    * Clinical data (sociodemographic characteristics, medical history, clinical examination, severity scores, and treatments); * Imaging data (at least one centralized and analyzable neuroimaging examination); * Biological data (at least one biological sample centralized in the biobank according to predefined quality standards).

    Time frame: From inclusion through completion of baseline data collection (during index hospitalization)

Secondary outcomes

  1. Proportion of patients managed according to the care bundle validated in the INTERACT 3 study, including the following components:

    * Early intensive blood pressure control; * Reversal of anticoagulation when applicable; * Maintenance of blood glucose within recommended targets (6.1-7.8 mmol/L for non-diabetic patients; 7.8-10.0 mmol/L for diabetic patients); * Body temperature \< 37.5 °C within one hour of hospital admission; * Systematic neurosurgical consultation.

    Time frame: Baseline

  2. Number of stored biological samples, by sample type

    Number of stored biological samples, by sample type (including citrated plasma, heparinized plasma, serum, DNA) and meeting predefined quality criteria

    Time frame: Through study completion, an average of ten years

  3. Volume of stored biological samples, by sample type

    Volume of stored biological samples, by sample type (including citrated plasma, heparinized plasma, serum, DNA) and meeting predefined quality criteria

    Time frame: Through study completion, an average of ten years

  4. Number of centralized and analyzable brain imaging studies

    Number of centralized and analyzable brain imaging studies, by imaging modality (CT, MRI), sequences, and availability of associated metadata.

    Time frame: Through study completion, an average of ten years

  5. Completion rate of clinical follow-up data

    Completion rate of clinical follow-up data, including the modified Rankin Scale (mRS), at 3, 6, and 24 months after intracerebral hemorrhage.

    Time frame: Through study completion, an average of ten years

  6. Number of participating centers achieving a data collection quality level > 80% across the three registry components (clinical, imaging, and biological data).

    Number of participating centers achieving a data collection quality level \> 80% across the three registry components (clinical, imaging, and biological data).

    Time frame: Through study completion, an average of ten years

  7. Number of research projects initiated or scientific publications produced using data from the TIPITCH registry.

    Number of research projects initiated or scientific publications produced using data from the TIPITCH registry.

    Time frame: Through study completion, an average of ten years

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2036, 120 months after the start.

Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 120 months is above that.

Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2026
First posted
Mar 3, 2026
StartActual
Apr 9, 2026
Primary completionEst.
Apr 2036
CompletionEst.
Apr 2036
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444853
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Apr 9, 2026
Primary completion
Apr 2036 (estimated)
Completion
Apr 2036 (estimated)
Last update
May 6, 2026

Study contacts

Marco PASI, Pr
Contact
m.pasi@chu-tours.fr
2.47.47.80.21 ext. +33
Sophie QUERAUD
Contact
s.queraud@chu-tours.fr
247470156 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion